These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17113896)

  • 1. Benefit evaluation of mass screening for prostate cancer: willingness-to-pay measurement using contingent valuation.
    Yasunaga H; Ide H; Imamura T; Ohe K
    Urology; 2006 Nov; 68(5):1046-50. PubMed ID: 17113896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to pay for mass screening for prostate cancer: a contingent valuation survey.
    Yasunaga H
    Int J Urol; 2008 Jan; 15(1):102-5; discussion 105. PubMed ID: 18184186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey.
    Yasunaga H; Sugihara T; Imamura T
    Urology; 2011 Jun; 77(6):1325-9. PubMed ID: 21507471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Women's anxieties caused by false positives in mammography screening: a contingent valuation survey.
    Yasunaga H; Ide H; Imamura T; Ohe K
    Breast Cancer Res Treat; 2007 Jan; 101(1):59-64. PubMed ID: 16821083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.
    Fautrel B; Clarke AE; Guillemin F; Adam V; St-Pierre Y; Panaritis T; Fortin PR; Menard HA; Donaldson C; Penrod JR
    J Rheumatol; 2005 Mar; 32(3):443-53. PubMed ID: 15742435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The measurement of willingness to pay for mass cancer screening with whole-body PET (positron emission tomography).
    Yasunaga H; Ide H; Imamura T; Ohe K
    Ann Nucl Med; 2006 Aug; 20(7):457-62. PubMed ID: 17037277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan.
    Tang CH; Liu JT; Chang CW; Chang WY
    Health Policy; 2007 Jul; 82(2):251-62. PubMed ID: 17084480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of prostate cancer screening with prostate-specific antigen.
    Imamura T; Yasunaga H
    Int J Urol; 2008 Apr; 15(4):285-8. PubMed ID: 18380812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicians' perceptions towards the impact of and willingness to pay for clinical computerization in Hong Kong.
    Leung GM; Yeung RY; Lai TY; Johnston JM; Tin KY; Wong IO; Woo PP; Ho LM
    Int J Med Inform; 2004 Jun; 73(5):403-14. PubMed ID: 15171982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who wants cancer screening with PET? A contingent valuation survey in Japan.
    Yasunaga H
    Eur J Radiol; 2009 Apr; 70(1):190-4. PubMed ID: 18093777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences of the absence of random assignment of bids on estimating willingness to pay using a discrete-choice question.
    Takemura S; Ohida T; Sone T; Fukuda T; Takemura Y
    Health Econ; 2005 Feb; 14(2):209-13. PubMed ID: 15386653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
    Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
    Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
    Kobayashi T; Goto R; Ito K; Mitsumori K
    Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
    Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening men for prostate cancer and colorectal cancer: is practice evidence-based?
    Chun FK; Suardi N; Perrotte P; Lebeau T; Guay JP; Benayoun S; Ramirez A; Bénard F; McCormack M; Valiquette L; Karakiewicz P
    Can J Urol; 2007 Dec; 14(6):3727-33. PubMed ID: 18163923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening.
    Frosch DL; Bhatnagar V; Tally S; Hamori CJ; Kaplan RM
    Arch Intern Med; 2008 Feb; 168(4):363-9. PubMed ID: 18299490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring the benefits of health promotion programmes: application of the contingent valuation method.
    Borghi J; Jan S
    Health Policy; 2008 Aug; 87(2):235-48. PubMed ID: 18295926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.